Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents

Atrial FibrillationHeart Failure

Long-Term Effects of Catheter Ablation vs Medical Therapy in Patients with Atrial Fibrillation and Heart Failure: A Reconstructed Individual Patient Data Meta-Analysis

Heart Rhythm

Itaya ED, Aranha F, Barbosa LM, Silva Sanchez GJ, Ternes CMP, d'Avila A

doi: 10.1016/j.hrthm.2026.05.006

Atrial Fibrillation

Atrial Fibrillation Progression in Patients with Device-Detected Subclinical Atrial Fibrillation: Insights from the ARTESiA Trial

Heart Rhythm

Boriani G, McIntyre WF, Ramasundarahettige C, Proietti M, Glotzer TV, Diemberger I, Nielsen JC, Essebag V, Granger CB, Sandhu RK, Benezet-Mazuecos J, Mabo P, Coutu B, Wong JA, Gold MR, Lopes RD, Healey JS, ARTESiA Investigators

doi: 10.1016/j.hrthm.2025.07.002

Atrial FibrillationFurther Publications

Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis

Circ Arrhythm Electrophysiol

Venier S, Defaye P, Lochon L, Benali R, Bisson A, Carabelli A, Diouf Y, Jacon P, Fauchier L

doi: 10.1161/CIRCEP.125.014101

Atrial Fibrillation

Integrated Care Management for Older Multimorbid Patients with Atrial Fibrillation: Rationale, Design and Baseline Characteristics for the Atrial Fibrillation Integrated Approach in Frail, Multimorbid and Polymedicated Older People (AFFIRMO) trial

Am Heart J

Proietti M, Lip GYH, Ainsworth J, Dan GA, Frost L, Graffigna G, Lucci D, Marin F, Potpara TS, Sanaullah A, Tokmakova M, Johnsen SP, Maggioni AP, AFFIRMO Study Investigators and Consortium

doi: 10.1016/j.ahj.2026.107356

Heart, Artery and Coronary DiseasesTherapy and Intervention

Sirolimus-Eluting Balloon With Provisional Stenting Versus Systematic Drug-Eluting Stent Implantation to Treat De Novo Coronary Lesions: A Randomized, Open-Label, Noninferiority Trial

Circulation

Spaulding C, Krackhardt F, Bogaerts K, Abdelaal E, Alfonso F, Briguori C, Bruch L, Cruden N, Den Hartog AW, Garot P, Godin M, Hildick-Smith D, Johnson T, Ladwiniec A, Linke A, Maart CA, Mashayekhi K, Meier P, Meunier L, Morgan K, O'Kane P, Puymirat E, Rissanen TT, Sabaté M, Schmitz T, Toth GG, Trevelyan J, Wanczura P, Marcus W, Wykrzykowska JJ, Urban P, Eccleshall S, SELUTION DeNovo Investigators

doi: 10.1161/CIRCULATIONAHA.126.079033

Atrial Fibrillation

Left atrial appendage occlusion versus NOACs in patients with atrial fibrillation: Rationale and design of the CATALYST Trial

Am Heart J

Reddy VY, Hylek E, Camm AJ, Halperin JL, Diener HC, Thaler D, Schmidt B, Hara H, Huisman MV, Price MJ, Lakkireddy D, Gage R, Zhao H, Jensen TP, Quintana M, Windecker S

doi: 10.1016/j.ahj.2026.107367

Atrial Fibrillation

Patients with persistent atrial fibrillation and metabolic comorbidities have an altered inflammatory state of atrial epicardial adipose tissue, which is linked to CT-attenuation

Cardiovasc Diabetol

Meulendijks ER, Fabrizi B, Bruns S, Eringa EC, Hoebe R, van den Boogert T, Wesselink R, Al-Shama RFM, de Vries TAC, Ernault AC, Niessen HWM, van Boven WJP, Driessen AHG, Zbairi I, Zappala P, Dey D, Isgum I, Planken RN, Krul SPJ, de Groot JR

doi: 10.1186/s12933-025-02985-1

Atrial Fibrillation

Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation

N Engl J Med

Verma A, Birnie DH, Jiang C, Heidbüchel H, Hindricks G, Kirchhof P, Healey JS, Wang Y, Dagres N, Deyell MW, Sanders P, Pathak RK, Koopman P, Nuyens D, Novak P, Amit G, Dussault C, Makanjee B, Quinn FR, Jolly U, Iden L, Kuniss M, Sharma M, Ha A, Essebag V, Champagne J, Hill MD, Smith EE, Wells GA, OCEAN Investigators

doi: 10.1056/NEJMoa2509688

Atrial FibrillationHeart Failure

External Validation of the REACT-HF Score for Predicting Heart Failure in Patients With Atrial Fibrillation

J Am Heart Assoc

Moschovitis G, Rigamonti E, Wiencierz A, Coslovsky M, Blum S, De Perna ML, Mayer-Melchiorre P, Vassalli G, Pedrazzini G, Healey JS, Reichlin T, Rodondi N, Müller A, Beer JH, Conte G, Stuber M, Schwenkglenks M, Mahfoud F, Sticherling C, Conen D, Osswald S, Kühne M, Krisai P, Swiss‐AF and BEAT‐AF Investigators

doi: 10.1161/JAHA.125.043058

Related content

Long-Term Effects of Catheter Ablation vs Medical Therapy in Patients with Atrial Fibrillation and Heart Failure: A Reconstructed Individual Patient Data Meta-Analysis

Atrial Fibrillation Progression in Patients with Device-Detected Subclinical Atrial Fibrillation: Insights from the ARTESiA Trial

Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis

Integrated Care Management for Older Multimorbid Patients with Atrial Fibrillation: Rationale, Design and Baseline Characteristics for the Atrial Fibrillation Integrated Approach in Frail, Multimorbid and Polymedicated Older People (AFFIRMO) trial

Sirolimus-Eluting Balloon With Provisional Stenting Versus Systematic Drug-Eluting Stent Implantation to Treat De Novo Coronary Lesions: A Randomized, Open-Label, Noninferiority Trial

Left atrial appendage occlusion versus NOACs in patients with atrial fibrillation: Rationale and design of the CATALYST Trial

Patients with persistent atrial fibrillation and metabolic comorbidities have an altered inflammatory state of atrial epicardial adipose tissue, which is linked to CT-attenuation

Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation

External Validation of the REACT-HF Score for Predicting Heart Failure in Patients With Atrial Fibrillation